JAK1 and acquired polycythemia vera: In 2011, the first JAK1/2 inhibitor, ruxolitinib, was approved for treatment of primary and secondary myelofibrosis (COMFORT studies) [62], and in 2014 and 2019, also for treatment of polycythemia vera (PV) and acute graft versus host disease (GvHD) [63,64].